Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Dna Script has 6 pending office actions in Biotechnology & Pharmaceuticals. The portfolio uses 6 distinct examiners and 5 distinct art units, indicating broad examiner coverage with some art-unit overlap.
ROBINSON, HOPE A is the busiest examiner, with 1 pending matter. Because no examiner has a larger listed assignment, practitioners should coordinate responses at the portfolio level while tailoring arguments to each file.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YAMASAKI, ROBERT J | 2 | 67.4% | +44.1% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629322 | Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 27d |
| 18709292 | NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANT AND USES THEREOF | ROBINSON, HOPE A | — |
| 18686319 | METHOD FOR GENERATING DOUBLE-STRANDED NUCLEIC ACID | ZAHORIK, AMANDA MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629322 | Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 27d |
| 18709292 | NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANT AND USES THEREOF | ROBINSON, HOPE A | — |
| 18686319 | METHOD FOR GENERATING DOUBLE-STRANDED NUCLEIC ACID | ZAHORIK, AMANDA MARY | — |
| 18568729 | ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES USING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE TRIPHOSPHATE MONOMERS | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18027594 | Stabilized N-Terminally Truncated Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof | SU-TOBON, QIWEN NMN | — |
| 17775845 | High Efficiency Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | — |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1657 | 2 |
| 1652 | 1 |
| 1637 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709292 | NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANT AND USES THEREOF | ROBINSON, HOPE A | 1652 | §103§112 | Final Rejection | — | Pending | May 10, 2024 |
| 18686319 | METHOD FOR GENERATING DOUBLE-STRANDED NUCLEIC ACID | ZAHORIK, AMANDA MARY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18568729 | ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES USING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE TRIPHOSPHATE MONOMERS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103§112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18027594 | Stabilized N-Terminally Truncated Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18034487 | Enzymatic Synthesis of Polynucleotide Probes | YU, DELPHINUS DOU YI | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 17775845 | High Efficiency Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 1657 | §112 | Final Rejection | — | Pending | May 10, 2022 |
| 17629322 | Increasing Long-Sequence Yields In Template-Free Enzymatic Synthesis of Polynucleotides | YAMASAKI, ROBERT J | 1657 | §103§112 | Non-Final OA | 27d | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDna Script has 7 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Robert J Yamasaki has the most, with 2 of Dna Script's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
